FDA Clears First Blood Test to Diagnose Alzheimer's Disease
The test measures two proteins, beta-amyloid and p-tau217, which are hallmarks of the disease
Experts believe this will increase access to Alzheimer's detection and reduce reliance on expensive PET scans and invasive spinal tapsThe Food and Drug Administration has given marketing clearance to the first blood test to help diagnose Alzheimer's disease.
On May 16, the agency announced clearance of the test — Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio — manufactured by the Pennsylvania-based biotechnology company Fujirebio Diagnostics. The test works by measuring proteins beta-amyloid and p-tau217, which are believed to be hallmarks of Alzheimer's disease.
Alzheimer's is a degenerative brain disease that is caused by complex brain changes following cell damage. It progressively affects memory, thinking and behavior seriously enough to interfere with daily tasks.
The blood test was cleared for use in people age 55 and older who exhibit signs and symptoms of the disease. The FDA said this new test can help increase access to Alzheimer's disease detection and reduce reliance on PET scans or spinal taps, which are more expensive and invasive.
!
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
'Nearly 7 million Americans are living with Alzheimer's disease and this number is projected to rise to nearly 13 million,' Dr. Michelle Tarver, director of the Center for Devices and Radiological Health, said in a statement. 'Today's clearance is an important step for Alzheimer's disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease.'
The FDA said that it conducted a study that evaluated 499 plasma samples from patients who were cognitively impaired and compared the results of the blood test with the results by PET scan or spinal tap.
Researchers found that the blood test was nearly 92% as accurate as a PET scan or spinal tap in detecting patients with Alzheimer's and over 97% as accurate in identifying patients who did not have the disease.
Dr. Richard Isaacson, a preventative neurologist who established one of the first Alzheimer's prevention clinics in the United States, told CNN that he has been using this blood test for years for research and applauded the FDA clearance.
'It can provide better clarity into whether a person experiencing memory loss may have Alzheimer's disease. They can take this test as a screening test,' he said. 'This is a much more simple screening test, with reasonable accuracy, to tell the physician that a person with cognitive decline has symptoms that are actually due to Alzheimer's disease.'
While the clearance is a step forward, Isaacson stressed that more research is necessary to determine how the blood test results should be interpreted and used to make medical decisions.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Epoch Times
4 hours ago
- Epoch Times
Cataracts: Leading Cause of Blindness—Here Are Its Early Signs
More than 20 million Americans aged 40 and older are affected by cataracts in one or both eyes. By age 75, nearly half of all Americans will develop the condition. Cataracts are a gradual clouding of the eye's natural lens—like looking through a foggy window that slowly becomes more blurred over time. This cloudiness blocks light from reaching the back of the eye, which is why vision becomes less clear.
Epoch Times
4 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
